Jennifer Lachey - Apr 11, 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Apr 11, 2022
Transactions value $
-$331,115
Form type
4
Date filed
4/13/2022, 04:36 PM
Previous filing
Apr 6, 2022
Next filing
May 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $1.59K +5.3K +6.18% $0.30* 91K Apr 11, 2022 Direct
transaction KROS Common Stock Sale -$87K -1.42K -1.56% $61.37 89.6K Apr 11, 2022 Direct F1, F2
transaction KROS Common Stock Sale -$62.9K -1.01K -1.13% $62.32 88.6K Apr 11, 2022 Direct F1, F3
transaction KROS Common Stock Sale -$147K -2.32K -2.61% $63.50 86.3K Apr 11, 2022 Direct F1, F4
transaction KROS Common Stock Sale -$35.9K -559 -0.65% $64.15 85.7K Apr 11, 2022 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -5.3K -6.91% $0.00 71.4K Apr 11, 2022 Common Stock 5.3K $0.30 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.97 to $61.935 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5).
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.975 to $62.97 inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.975 to $63.865 inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.00 to $64.49 inclusive.
F6 Immediately exercisable.